The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells
Open accessAbstract
The envelope glycoprotein of human immunodeficiency virus (HIV) consists of an exterior glycoprotein (gp120) and a trans-membrane domain (gp41) and has an important role in viral entry into cells. HIV-1 entry has been validated as a clinically relevant anti-viral strategy for drug discovery. In the present work, several 2'-F substituted RNA aptamers that bind to the HIV-1(BaL) gp120 protein with nanomole affinity were isolated from a RNA library by the SELEX (Systematic Evolution of Ligands by EXponential enrichment) procedure. From two of these aptamers we created a series of new dual inhibitory function anti-gp120 aptamer-siRNA chimeras. The aptamers and aptamer-siRNA chimeras specifically bind to and are internalized into cells expressing HIV gp160. The Dicer-substrate siRNA delivered by the aptamers is functionally processed by Dicer, resulting in specific inhibition of HIV-1 replication and infectivity in cultured CEM T-cells and primary blood mononuclear cells (PBMCs). Moreover, we have introduced a 'sticky' sequence onto a chemically synthesized aptamer which facilitates attachment of the Dicer substrate siRNAs for potential multiplexing. Our results provide a set of novel inhibitory agents for blocking HIV replication and further validate the use of aptamers for delivery of Dicer substrate siRNAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
Dalgleish, A. G., Beverley, P. C. L., Clapham, P. R., Crawford, D. H., Greaves, M. F., & Weiss, R. A. (1984) · Nature · doi:10.1038/312763a0 · Cited by 3,533
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T., Gluckman, J.-C., & Montagnier, L. (1984) · Nature · doi:10.1038/312767a0 · Cited by 2,436
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
Wyatt, R., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1884 · Cited by 1,598
Identification of host proteins required for HIV infection through a functional genomic screen
Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., Engelman, A., Xavier, R. J., Lieberman, J., & Elledge, S. J. (2008) · Science · doi:10.1126/science.1152725 · Cited by 1,449 · cited 1×
“It has been demonstrated that more than 250 HIV-dependency factors (HDFs) are required by HIV infection ( 48 ).”
BackgroundChan, D. C., & Kim, P. S. (1998) · Cell · doi:10.1016/s0092-8674(00)81430-0 · Cited by 1,277
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Cited by
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Self-citationThe current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Self-citationAnalysis of aptamer discovery and technology
Dunn, M. R., Jimenez, R. M., & Chaput, J. C. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0076 · Cited by 938
Aptamer in Bioanalytical Applications
Iliuk, A. B., Hu, L., & Tao, W. A. (2011) · Analytical Chemistry · doi:10.1021/ac201057w · Cited by 762
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
T memory stem cells in health and disease
Gattinoni, L., Speiser, D. E., Lichterfeld, M., & Bonini, C. (2017) · Nature Medicine · doi:10.1038/nm.4241 · Cited by 620
Nucleic Acid Based Molecular Devices
Krishnan, Y., & Simmel, F. C. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.200907223 · Cited by 572
Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
Sun, H., Zhu, X., Lu, P. Y., Rosato, R. R., Tan, W., & Zu, Y. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.32 · Cited by 541
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
Self-citationRNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Prodrugs for improving tumor targetability and efficiency
Mahato, R., Tai, W., & Cheng, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.02.002 · Cited by 353
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
RNAi and small interfering RNAs in human disease therapeutic applications
Lares, M. R., Rossi, J. J., & Ouellet, D. L. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.009 · Cited by 277
Self-citationAutomated physics-based design of synthetic riboswitches from diverse RNA aptamers
Espah Borujeni, A., Mishler, D. M., Wang, J., Huso, W., & Salis, H. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1289 · Cited by 264
Neff, C. P., Zhou, J., Remling, L., Kuruvilla, J., Zhang, J., Li, H., Smith, D. D., Swiderski, P., Rossi, J. J., & Akkina, R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001581 · Cited by 259
Self-citationRockey, W. M., Hernandez, F. J., Huang, S.-Y., Cao, S., Howell, C. A., Thomas, G. S., Liu, X. Y., Lapteva, N., Spencer, D. M., Mcnamara, J. O., et al. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0313 · Cited by 139
Nucleotide Bias Observed with a Short SELEX RNA Aptamer Library
Thiel, W. H., Bair, T., Wyatt Thiel, K., Dassie, J. P., Rockey, W. M., Howell, C. A., Liu, X. Y., Dupuy, A. J., Huang, L., Owczarzy, R., et al. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0288 · Cited by 66
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Metadata
- Authors
- Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C. P., Akkina, R., & Rossi, J. J.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-21
- Volume
- 37
- Issue
- 9
- Pages
- 3094-3109
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2137109655
- Cited by
- 267
- References
- 44
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.